United Therapeutics Corp

자세한 내용은 United Therapeutics Corp 회사

United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.

회사 정보

종목 코드 UTHR

회사 이름United Therapeutics Corp

상장일Jun 17, 1999

설립일1996

CEODr. Martine A. Rothblatt

직원 수1305

유형Ordinary Share

회계 연도 종료Jun 17

주소1000 Spring St

도시SILVER SPRING

증권 거래소NASDAQ Global Select Consolidated

국가United States of America

우편 번호20910

전화13016089292

웹사이트https://www.unither.com/

종목 코드 UTHR

상장일Jun 17, 1999

설립일1996

회사 임원

이름

이름/직위

직위

주식 보유

변동

Dr. Martine A. Rothblatt

Chairman of the Board, Chief Executive Officer

666.42K

-0.06%

Mr. Paul A. Mahon, J.D.

Executive Vice President, General Counsel, Corporate Secretary

36.78K

--

Mr. Richard A. Giltner

Independent Director

19.38K

+11.27%

Prof. Nilda Mesa, J.D.

Independent Director

4.88K

-11.67%

The Hon. Dr. Louis W. Sullivan, M.D.

Independent Director

3.20K

--

Mr. Michael Benkowitz

President, Chief Operating Officer

2.65K

+2.76%

Mr. Christopher Patusky, J.D.

Lead Independent Vice Chairman of the Board

2.00K

-0.20%

Gov. Thomas G. (Tommy) Thompson, J.D.

Independent Director

--

Mr. Christopher A. Causey

Independent Director

--

Mr. James C. Edgemond

Chief Financial Officer, Treasurer

--

이름

이름/직위

직위

주식 보유

변동

Dr. Martine A. Rothblatt

Chairman of the Board, Chief Executive Officer

666.42K

-0.06%

Mr. Paul A. Mahon, J.D.

Executive Vice President, General Counsel, Corporate Secretary

36.78K

--

Mr. Richard A. Giltner

Independent Director

19.38K

+11.27%

Prof. Nilda Mesa, J.D.

Independent Director

4.88K

-11.67%

The Hon. Dr. Louis W. Sullivan, M.D.

Independent Director

3.20K

--

Mr. Michael Benkowitz

President, Chief Operating Officer

2.65K

+2.76%

수익 분석

통화: USD마지막 업데이트: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

데이터 없음

지역별USD

이름

수익

비율

United States

749.60M

94.36%

Rest of World

44.80M

5.64%

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Fri, May 16

주주

주주 유형

주주

비율

BlackRock Institutional Trust Company, N.A.

9.93%

The Vanguard Group, Inc.

9.84%

Avoro Capital Advisors LLC

5.93%

State Street Global Advisors (US)

4.95%

Renaissance Technologies LLC

4.67%

Other

64.69%

주주

비율

BlackRock Institutional Trust Company, N.A.

9.93%

The Vanguard Group, Inc.

9.84%

Avoro Capital Advisors LLC

5.93%

State Street Global Advisors (US)

4.95%

Renaissance Technologies LLC

4.67%

Other

64.69%

주주 유형

주주

비율

Investment Advisor/Hedge Fund

48.91%

Investment Advisor

36.17%

Hedge Fund

7.48%

Pension Fund

4.28%

Individual Investor

1.75%

Research Firm

1.52%

Bank and Trust

1.46%

Sovereign Wealth Fund

1.23%

Insurance Company

0.12%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

1315

46.61M

103.33%

-1.16M

2025Q1

1369

46.67M

103.49%

-1.81M

2024Q4

1344

46.07M

102.60%

-3.00M

2024Q3

1278

45.38M

101.97%

-7.63M

2024Q2

1219

48.02M

108.26%

-2.92M

2024Q1

1151

47.12M

106.59%

-2.41M

2023Q4

1127

46.52M

99.01%

-2.26M

2023Q3

1094

46.35M

98.80%

-3.96M

2023Q2

1068

46.82M

99.96%

-3.45M

2023Q1

1055

47.11M

101.08%

-1.09M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

BlackRock Institutional Trust Company, N.A.

4.48M

9.93%

+12.87K

+0.29%

Mar 31, 2025

The Vanguard Group, Inc.

4.44M

9.84%

+15.26K

+0.34%

Mar 31, 2025

Avoro Capital Advisors LLC

2.67M

5.93%

-85.30K

-3.09%

Mar 31, 2025

State Street Global Advisors (US)

2.23M

4.95%

+30.71K

+1.40%

Mar 31, 2025

Renaissance Technologies LLC

2.11M

4.67%

+17.60K

+0.84%

Mar 31, 2025

Wellington Management Company, LLP

2.03M

4.49%

-437.48K

-17.76%

Mar 31, 2025

Geode Capital Management, L.L.C.

1.22M

2.71%

+85.70K

+7.53%

Mar 31, 2025

Fidelity Management & Research Company LLC

1.03M

2.29%

-283.67K

-21.55%

Mar 31, 2025

AQR Capital Management, LLC

908.45K

2.01%

-67.00K

-6.87%

Mar 31, 2025

LSV Asset Management

902.32K

2%

-6.40K

-0.70%

Mar 31, 2025

295.520USD

United Therapeutics Corp

295.520

개요

회사

금융